OTCQB: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.

About

Latest News

GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
Apr 24, 2019 • 7:30 EDT | Read More

GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial
Apr 8, 2019 • 7:30 EDT | Read More

Investors

GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range